Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.
High concentrations of lipoprotein(a) (Lp(a)) represent an important independent and causal risk factor associated with adverse outcome in atherosclerotic cardiovascular disease (CVD). Effective Lp(a) lowering drug treatment is not available. Lipoprotein apheresis (LA) has been proven to prevent cardiovascular events in patients with Lp(a)-hyperlipoproteinemia (Lp(a)-HLP) and progressive CVD. Here we present the course of a male patient with established peripheral arterial occlusive disease (PAOD) at the early age of 41 and coronary artery disease (CAD), who during follow-up developed over 2 years a progressive syndrome of cerebellar and spinal cord deficits against the background of multifactorial cardiovascular risk including positive family history of CVD. Spastic tetraplegia and dependency on wheel chair and nursing care represented the nadir of neurological deficits. All conventional risk factors including LDL-cholesterol had already been treated and after exclusion of other causes, genetically determined Lp(a)-HLP was considered as the major underlying etiologic factor of ischemic vascular disease in this patient including spinal cord ischemia with vascular myelopathy. Treatment with an intensive regimen of chronic LA over 4.5 years now was successful to stabilize PAOD and CAD and led to very impressive neurologic and overall physical rehabilitation and improvement of quality of life.Measurement of Lp(a) concentration must be recommended to assess individual cardiovascular risk. Extracorporeal clearance of Lp(a) by LA should be considered as treatment option for select patients with progressive Lp(a)-associated ischemic syndromes.
Medical Care Center Kempten-Allgäu, Kempten, Germany. heigl@mvz-kempten.de.
Franz
F
Heigl
Medical Care Center Kempten-Allgäu, Kempten, Germany.
Reinhard
R
Hettich
Clinic for Neurology Dietenbronn, Academic Hospital of the University of Ulm, Schwendi, Germany.
Erich
E
Mauch
Apheresis Research Institute, Cologne, Germany.|1st Department Internal Medicine, University of Mainz, Mainz, Germany.
Reinhard
R
Klingel
Apheresis Research Institute, Cologne, Germany.
Cordula
C
Fassbender
D000328:Adult; D015415:Biomarkers / Q000097:blood; D001781:Blood Component Removal; D002908:Chronic Disease; D003324:Coronary Artery Disease / Q000209:etiology; D004185:Disability Evaluation; D018450:Disease Progression; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D009460:Neurologic Examination; D058729:Peripheral Arterial Disease / Q000209:etiology; D011788:Quality of Life; D020127:Recovery of Function; D020760:Spinal Cord Ischemia / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000534:rehabilitation; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D017270:Lipoprotein(a)
Cardiovascular disease; Lipoprotein (a); Lipoprotein apheresis; Spinal cord ischemia; Vascular myelopathy